Since the first report describing TRAIL in 1995 [5], the majority of research has explored this molecule as an anti-cancer therapeutic, capitalizing on its ability to selectively induce apoptosis in a broad range of tumor cell lines with minimal effect on normal cells [4, 5, 9]. The gene discussed is TNFSF10; the disease is neoplasm.